ATE362770T1 - Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen - Google Patents

Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Info

Publication number
ATE362770T1
ATE362770T1 AT01909098T AT01909098T ATE362770T1 AT E362770 T1 ATE362770 T1 AT E362770T1 AT 01909098 T AT01909098 T AT 01909098T AT 01909098 T AT01909098 T AT 01909098T AT E362770 T1 ATE362770 T1 AT E362770T1
Authority
AT
Austria
Prior art keywords
relaxin
diseases
vaso
construction
treatment
Prior art date
Application number
AT01909098T
Other languages
English (en)
Inventor
Kirk Conrad
Martyn Lewis
Elaine Unemori
Xinfan Huang
Carol Tozzi
Original Assignee
Bas Medical Inc
Univ Pittsburgh
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bas Medical Inc, Univ Pittsburgh, Univ New Jersey Med filed Critical Bas Medical Inc
Application granted granted Critical
Publication of ATE362770T1 publication Critical patent/ATE362770T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01909098T 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen ATE362770T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18140800P 2000-02-09 2000-02-09
US20028400P 2000-04-28 2000-04-28
US24221600P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
ATE362770T1 true ATE362770T1 (de) 2007-06-15

Family

ID=27391410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909098T ATE362770T1 (de) 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Country Status (7)

Country Link
US (2) US6723702B2 (de)
EP (1) EP1253929B1 (de)
AT (1) ATE362770T1 (de)
AU (1) AU2001236886A1 (de)
CA (1) CA2397200C (de)
DE (1) DE60128540T2 (de)
WO (1) WO2001058468A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6124401A (en) * 2000-05-09 2001-11-20 Nitromed Inc Infrared thermography and methods of use
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ITFI20030328A1 (it) * 2003-12-24 2005-06-25 Mario Bigazzi Uso della relaxina come adiuvante nella differenziazione
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1765149B1 (de) * 2004-03-19 2016-09-28 University Of Pittsburgh Verwendung von relaxin zur erhöhung der arteriencompliance
EP1729817B1 (de) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Relaxin-gen enthaltendes genverabreichungssystem und pharmazeutische zusammensetzung, die relaxin verwendet
WO2005115435A2 (en) * 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
WO2006074341A2 (en) * 2005-01-07 2006-07-13 Glaxo Group Limited Novel use
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
KR20090033886A (ko) * 2006-07-25 2009-04-06 알콘 리서치, 리미티드 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제
CN101679095B (zh) * 2007-05-11 2012-09-05 康宁股份有限公司 用改进的端部支承条件控制溢流槽下弯
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
AU2009246333B2 (en) * 2008-05-16 2013-05-09 Corthera, Inc. Method of promoting wound healing
US8574851B2 (en) 2008-11-24 2013-11-05 Corthera, Inc. Prediction and prevention of preeclampsia
WO2010105081A1 (en) * 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
KR101800040B1 (ko) 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013033324A2 (en) * 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
WO2014022294A1 (en) * 2012-07-31 2014-02-06 Novartis Ag Treating inflammation using serelaxin
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
CN116802289A (zh) * 2020-10-15 2023-09-22 东北大学 用于增加胶原蛋白产量的工程化细胞
EP4791358A1 (de) 2023-09-15 2026-08-19 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Relaxin-arzneimittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
DE3236264A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur gewinnung von relaxin
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
WO1989007945A1 (en) * 1988-02-26 1989-09-08 Genentech, Inc. Human relaxin formulation
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
CA2145515A1 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
WO1995007711A1 (en) 1993-09-14 1995-03-23 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting blood vessel blockage using a polypeptide
ES2187667T3 (es) * 1995-08-15 2003-06-16 Connetics Corp Uso de relaxina para estimular angiogenesis.
US6251863B1 (en) * 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin

Also Published As

Publication number Publication date
US20020019349A1 (en) 2002-02-14
AU2001236886A1 (en) 2001-08-20
EP1253929B1 (de) 2007-05-23
EP1253929A4 (de) 2003-03-05
EP1253929A1 (de) 2002-11-06
DE60128540D1 (de) 2007-07-05
CA2397200C (en) 2010-11-23
US20040266685A1 (en) 2004-12-30
HK1051001A1 (en) 2003-07-18
CA2397200A1 (en) 2001-08-16
DE60128540T2 (de) 2008-01-31
US6723702B2 (en) 2004-04-20
WO2001058468A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ATE371462T1 (de) Verbesserung der herstellung von endogenen gonadotropin
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
DE60115842D1 (de) Ventilanordnung
TR200101120T2 (tr) Serin proteaz inhibitörü
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DE60143990D1 (de) Neue therapeutische verwendung von smr-1 peptide
NO994640D0 (no) Hostestillende midler
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE454155T1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE324112T1 (de) Topische behandlung bei der mastalgie
ATE484292T1 (de) Chorionic gonadotropin zur behandlung des chronischen schmerzsyndroms des beckens
SE0004101D0 (sv) New use
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
EP1854476A3 (de) Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
ATE283059T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von reizbarkeit
RU2001118219A (ru) Ингибитор ангиогенеза
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253929

Country of ref document: EP

EEFA Change of the company name